arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Xilio Therapeutics, Inc.

XLO
$9.16 ▼ -0.01 (-0.05%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
26 Visible periods
25 Metrics
Peer-ranked Benchmarks
Price Chart
11
Health
Poor
Bearish
auto_awesome

Analytical Summary

Xilio Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $149.7M
Dividend Yield
Revenue Growth 331.7%
Op. Margin -111.6%
ROIC -15.4%
FCF / Share $-1.40
Trailing P/E
Price / Book 0.7x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

26-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$12.65M
↑ +331.7%
Net Income Profit after all expenses
$-9.53M
↑ +28.2%
Operating Margin Operating profit as % of sales
-111.6%
↓ -29.0% 2th
FCF / Share Free cash flow per share
$-1.40
↓ -1053.8%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
5
Returns
9
Cash Quality
28

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 26 quarters